Stardust Solar Energy Inc. announced a non-brokered private placement to raise up to $641,000 by issuing 641 senior secured convertible debenture units. Each unit includes a $1,000 debenture and 13,333 common share purchase warrants. The funds will be used to repay outstanding principal and interest on previous convertible debentures issued in February 2026. The offering is subject to regulatory approvals and will have a statutory hold period before resale is allowed. This move aims to manage the company's debt and support its ongoing renewable energy initiatives.
Stardust Solar's private placement announcement comes with this market context from Pluang's Energy sector. As of Sep 30, 2026 01:21 WIB, 38 priced Energy-sector US stocks were tracked, with 4 rising and 34 falling. Notable prices include MPLX at USD 56.85, Shell PLC at USD 95.16 with a typical hold time of 90 days and 90% buy order activity, and Chevron Corp at USD 204.14 with a typical hold time of 101 days.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
